These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 3542943)

  • 1. Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria.
    Leigh DA; Emmanuel FX; Petch VJ
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():117-21. PubMed ID: 3542943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complicated urinary tract infections treated with extended-release ciprofloxacin with emphasis on Pseudomonas aeruginosa.
    Saltzstein D; Wachs B; Perroncel R; Benson A; Herrington J; Haverstock D; Pertel P
    J Chemother; 2007 Dec; 19(6):694-702. PubMed ID: 18230553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection.
    Brown EM; Morris R; Stephenson TP
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():123-7. PubMed ID: 3804900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the usefulness of a novel injectable cephalosporin, E1040, and ceftazidime for management of complicated urinary tract infections caused by Pseudomonas aeruginosa and Proteus mirabilis by using the rat urolithiasis model.
    Satoh M; Munakata K; Takeuchi H; Yoshida O
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1580-3. PubMed ID: 1510458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of norfloxacin vs. ciprofloxacin in complicated urinary tract infection.
    Schaeffer AJ; Anderson RU
    Urology; 1992 Nov; 40(5):446-9. PubMed ID: 1441044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.
    Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Screen P; Becker N; August R
    J Clin Pharmacol; 1988 Feb; 28(2):179-89. PubMed ID: 3360968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland.
    Nicoletti J; Kuster SP; Sulser T; Zbinden R; Ruef C; Ledergerber B; Weber R
    Swiss Med Wkly; 2010; 140():w13059. PubMed ID: 20648400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria.
    Preheim LC; Cuevas TA; Roccaforte JS; Mellencamp MA; Bittner MJ
    Am J Med; 1987 Apr; 82(4A):295-300. PubMed ID: 3555051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and laboratory study of tobramycin in the treatment of infections due to gram-negative organisms.
    Marrie TJ; Gurwith MJ; Ronald AR; Stiver HG; Lank B; Fox L
    Can Med Assoc J; 1977 Jul; 117(2):138-43. PubMed ID: 406032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.
    Giamarellou H; Galanakis N; Dendrinos C; Stefanou J; Daphnis E; Daikos GK
    Eur J Clin Microbiol; 1986 Apr; 5(2):232-5. PubMed ID: 2941288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciprofloxacin (BAY 09867): clinical evaluation in urinary tract infections due to Pseudomonas aeruginosa.
    Guibert JM; Destree DM; Acar JF
    Chemioterapia; 1987 Jun; 6(2 Suppl):524-5. PubMed ID: 3151352
    [No Abstract]   [Full Text] [Related]  

  • 13. The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin.
    Leigh DA; Emmanuel FX
    J Antimicrob Chemother; 1984 May; 13 Suppl B():85-8. PubMed ID: 6234280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy of urinary tract infection by gram-negative bacilli].
    Hirata K; Kumazawa J
    Iryo; 1966 Nov; 20(11):1146-50. PubMed ID: 4860163
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of a novel injectable cephalosporin, Cefclidin, on the experimental complicated urinary tract infections with urinary stones caused by Pseudomonas aeruginosa and Proteus mirabilis.
    Satoh M; Munakata K; Takeuchi H; Yoshida O
    Hinyokika Kiyo; 1994 Aug; 40(8):689-94. PubMed ID: 7942366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral ciprofloxacin versus intravenous therapy with other non-quinolone agents: a study of 291 infections.
    Lorian V; Pavletich K
    Drugs Exp Clin Res; 1994; 20(5):209-14. PubMed ID: 7875058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with indanyl carbenicillin in urinary tract infections.
    Giamarellou E; Papazachos G; Piperakis G; Daikos G
    Curr Med Res Opin; 1976; 4(2):170-6. PubMed ID: 776540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with ciprofloxacin in the treatment of various infections caused mainly by Pseudomonas aeruginosa.
    Giamarellou H; Daphnis E; Dendrinos C; Daikos GK
    Drugs Exp Clin Res; 1985; 11(5):351-6. PubMed ID: 2941264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volunteer and clinical studies with carfecillin: a new orally administered ester of carbenicillin.
    Wilkinson PJ; Reeves DS; Wise R; Allen JT
    Br Med J; 1975 May; 2(5965):250-2. PubMed ID: 805625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy results with nalidixic acid in chronic urinary tract infection].
    Broghammer H
    Arzneimittelforschung; 1968 Sep; 18(9):1139-43. PubMed ID: 4885373
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.